Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Shares Gap Down – Here’s What Happened

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY)’s share price gapped down prior to trading on Wednesday . The stock had previously closed at $8.91, but opened at $8.29. Shionogi & Co., Ltd. Unsponsored ADR shares last traded at $8.51, with a volume of 7,693 shares trading hands.

Analyst Upgrades and Downgrades

SGIOY has been the topic of several recent analyst reports. The Goldman Sachs Group upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR to a “hold” rating in a research note on Wednesday, April 8th. Zacks Research upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a “strong sell” rating to a “hold” rating in a research note on Monday, May 25th. Two research analysts have rated the stock with a Hold rating, According to MarketBeat, Shionogi & Co., Ltd. Unsponsored ADR has an average rating of “Hold”.

Shionogi & Co., Ltd. Unsponsored ADR Price Performance

The company has a market capitalization of $14.70 billion, a PE ratio of 10.80, a price-to-earnings-growth ratio of 3.42 and a beta of 0.08. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.84 and a quick ratio of 5.21. The company’s 50 day simple moving average is $9.89 and its 200 day simple moving average is $9.89.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) last announced its quarterly earnings results on Tuesday, May 12th. The company reported $0.18 EPS for the quarter, beating the consensus estimate of $0.15 by $0.03. The company had revenue of $881.71 million for the quarter, compared to analyst estimates of $895.52 million. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 41.08% and a return on equity of 14.09%. As a group, sell-side analysts predict that Shionogi & Co., Ltd. Unsponsored ADR will post 0.81 earnings per share for the current year.

Shionogi & Co., Ltd. Unsponsored ADR Company Profile

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company’s product portfolio spans both established and innovative therapies.